EBS EVP reports 313-share tax withholding

Emergent BioSolutions EVP Coleen Glessner reported a small share disposition related to taxes.

Accepted by SEC EDGAR 03/03/2026 - 04:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Emergent BioSolutions EVP Coleen Glessner reported a small share disposition related to taxes. On the vesting of restricted stock units, 313 shares of common stock were withheld at $8.15 per share to cover tax obligations. After this tax-withholding disposition, she directly owns 112,307 common shares.

Insider Trade Summary

Exercise Price or Tax Liability: 313 shares

Exercise Price or Tax Liability 1 txn

Insider Glessner Coleen

Role EVP, Quality & Ethics, and CPL

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	313	$8.15	$3K

Holdings After Transaction: Common Stock — 112,307 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Emergent BioSolutions (EBS) report for Coleen Glessner?

Emergent BioSolutions reported a tax-related share disposition by EVP Coleen Glessner. 313 common shares were withheld upon vesting of restricted stock units to cover taxes, rather than sold in the open market. She continues to hold a substantial direct share position afterward.

How many Emergent BioSolutions (EBS) shares were involved in Coleen Glessner’s Form 4?

The Form 4 shows 313 common shares were disposed of through tax withholding. These shares were withheld upon vesting and settlement of restricted stock units, according to the footnote, and were not reported as an open-market sale transaction.

What price was used for the tax-withholding disposition in EBS insider filing?

The tax-withholding disposition used a price of $8.15 per share for 313 common shares. This figure reflects the value applied to shares withheld to satisfy taxes triggered by restricted stock unit vesting and settlement for executive Coleen Glessner.

How many Emergent BioSolutions (EBS) shares does Coleen Glessner own after this transaction?

After the tax-withholding disposition, Coleen Glessner directly owns 112,307 common shares of Emergent BioSolutions. This post-transaction holding reflects her remaining direct equity stake following the withholding of 313 shares to cover taxes on vested restricted stock units.

Was the EBS insider transaction an open-market sale by Coleen Glessner?

No, the transaction was a tax-withholding disposition, not an open-market sale. The filing and footnote explain that 313 shares were withheld to pay taxes associated with vesting and settlement of restricted stock units granted to Coleen Glessner.

What does transaction code F mean in the Emergent BioSolutions (EBS) Form 4?

In this Form 4, code F indicates payment of a tax liability or exercise price by delivering securities. Here, 313 common shares were withheld to cover taxes when Coleen Glessner’s restricted stock units vested and settled, rather than being sold on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glessner Coleen

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Quality & Ethics, and CPL

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026	03/02/2026	F		313(1)	D	$8.15	112,307	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.